B

Bullfrog AI Holdings, Inc.
NASDAQ:BFRG

Watchlist Manager
Bullfrog AI Holdings, Inc.
NASDAQ:BFRG
Watchlist
Price: 0.872 USD -0.93%
Market Cap: 9.9m USD

Bullfrog AI Holdings, Inc.
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Bullfrog AI Holdings, Inc.
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
B
Bullfrog AI Holdings, Inc.
NASDAQ:BFRG
Free Cash Flow
-$5.6m
CAGR 3-Years
-145%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Free Cash Flow
$1.4B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
38%
Inspire Medical Systems Inc
NYSE:INSP
Free Cash Flow
$98.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Free Cash Flow
$266.7m
CAGR 3-Years
30%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Free Cash Flow
$93.8m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
19%
W
Waystar Holding Corp
NASDAQ:WAY
Free Cash Flow
$142.5m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Bullfrog AI Holdings, Inc.
Glance View

Market Cap
9.1m USD
Industry
Health Care

BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 2 full-time employees. The company went IPO on 2023-02-14. The firm is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. Its platform technology, bfLEAP, is an analytical AI/ML platform, which is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize it against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targeting Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

BFRG Intrinsic Value
0.036 USD
Overvaluation 96%
Intrinsic Value
Price
B

See Also

What is Bullfrog AI Holdings, Inc.'s Free Cash Flow?
Free Cash Flow
-5.6m USD

Based on the financial report for Dec 31, 2024, Bullfrog AI Holdings, Inc.'s Free Cash Flow amounts to -5.6m USD.

What is Bullfrog AI Holdings, Inc.'s Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-145%

Over the last year, the Free Cash Flow growth was 7%. The average annual Free Cash Flow growth rates for Bullfrog AI Holdings, Inc. have been -145% over the past three years .

Back to Top